Nasdaq
$3.98▲ 1.79%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $50.9MShares out 12.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 3d agoRegular26.10.22 04:424Ownership#●●●
Clene Inc.
Clene Inc. executive Robert Dee Etherington reported a change in beneficial ownership of securities effective October 20, 2026. This filing serves as a formal disclosure of insider equity movement under Form 4.…more
$3.98+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoRegular26.10.22 04:324Ownership
Clene Inc.
Clene Inc. insider Mark Mortenson filed a Form 4 on October 21, 2026, reporting a change in beneficial ownership of securities as of October 20, 2026. This filing formalizes the recent changes in the executive's equity holdings.…more
$3.98+1.79%vs prev closeView filingShare - 3d agoRegular26.10.22 04:304Ownership
Clene Inc.
Clene Inc. executive Morgan R. Brown reported a change in beneficial ownership of company securities effective October 20, 2026. This filing serves as a standard disclosure of insider transactions and does not involve any material changes to the company's capital structure or financial position.…more
$3.98+1.79%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●
Clene Submits NDA to FDA for ALS Treatment CNM-Au8
Clene has submitted a New Drug Application (NDA) to the FDA for its ALS treatment candidate, CNM-Au8. The company is seeking accelerated approval based on clinical and biomarker data.…more
$3.98+1.79%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.22Pre-market26.09.22 21:00
●●●●●●●● ●●●●● ●●●●●●
Clene announced its participation in the ROTH and Lytham Partners investor conferences to conduct presentations and one-on-one meetings. This is a routine investor relations event with no immediate material impact on the stock price.…more
$3.98+1.79%vs prev close - 9.21Pre-market26.09.21 21:30
●●●●●●●● ●●●●● ●●●●●●
Clene has completed a $4 million registered direct offering involving existing shareholders and company insiders. The proceeds extend the company's cash runway through the first quarter of 2027, supporting its ongoing FDA regulatory process.…more
$3.98+1.79%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report